
About
John Sundy is currently Chief Medical Officer and Head of Research and Development at Seicmic Therapeutic, a machine learning immunology company and is Adjunct Professor of Medicine in the Division of Rheumatology and Immunology at Duke University School of Medicine. He was a tenured faculty member at Duke University before moving to the biotech industry in 2014. Between 2014 and 2021, he held several management positions including Senior Vice President at Gilead Sciences, and Chief Medical Officer at Pandion Therapeutics.
He is also a director of Neutrolis, Inc, and the Childhood Arthritis and Rheumatology Research Alliance, and serves on the Steering Committee of the NIH Immune Tolerance Network.
John Sundy obtained a B.S. in biology from Bucknell University and a M.D./Ph.D from Hahnemann University with a specialization in immunology, and completed clinical training in rheumatology and allergy/immunology at Duke.
Personal Details
Qualifications & Experience
Other directorships (state)
(only entities turnover at least $5m p/a)
Working history
Committee/s
| Company | Committee | Role | Appointment Date | Resignation Date |
|---|---|---|---|---|
| Sanofi | Board | Member | 01/04/2024 | |
| Sanofi | Other | Member | 01/04/2024 |